Tuesday · 8:30

Medicine has evolved. Market access must do the same.
Regulators, payers and HTAs are changing. Clear themes are emerging, including harmonisation, increasingly bespoke agreements and the consideration of new forms of evidence. But these are not solutions - health systems remain close to breaking point, with industry and payers often failing to reach agreement on value and affordability.

We must now harness maturing RWE and digital capabilities to advance access approaches and create a more affordable, value-driven system.

eyeforpharma Barcelona is the only event that brings together market access executives, key market access authorities and pharma leadership from across the commercial and clinical spectrum to accelerate harmonisation and spark our next evolutionary leap forward.

Brochure: https://go.evvnt.com/547459-3?pid=5731

Pharma Silver Pass: EUR 1999.0,
Solution Provider Silver Pass: EUR 2399.0

Speakers: Martin Price VP, Health Economics, Market Access and Reimbursement, EMEA Janssen, Tamir Singer Head of Commercial Access and Value, Commercial Medicines Directorate NHS England, Anna Papin di Pompeo Vice President, Government Affairs - Europe Merck Group, Giuseppe Rosano Member CVWP EMA, Lara Pippo Head Market Access, Italy CSL Behring, Adam Kundzewicz Head of Strategic Market Access Initiatives Boehringer Ingelheim, Alexander Natz Secretary General EUCOPE, Wim Goettsch Special Advisor HTA; Affiliate Associate Professor International Collaboration in HTA, Universiteit Utrecht ZINL, Rosie Lovett Senior Scientifc Advisor NICE, Daniel Jackson Head of Access Operations - Europe UCB, Stefan Holmstrom Global Head, PRO Excellence and HTA Strategy Astellas, Raquel Riol Head of Market Access, AMESA Region Sanofi, Jorg Mahlich Head of HEOR Janssen, Pall Jonsson Associate Director, Science Policy and Research NICE, Tarry Ahuja RWE Lead and Manager, Policy and Product Development Canadian Agency for Drugs and Technology in Health